Pharming reports Q1 results
Slightly above 715827949 percent of Pharming Group's retail investors are aggressively looking to sell. The analysis of the overall investor sentiment regarding Pharming Group NV suggests that quite a large number of traders are panicking. Pharming Group's investing sentiment overview a quick insight into current market opportunities from investing in Pharming Group NV. Many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Pharming reports Q1 revenue growth of 31 percent to 55.6M. Loss per share stands at 0.019.
Read at seekingalpha.com
 |
Pharming Group Fundamental Analysis
We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Pharming Group NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.
Peers
Pharming Group Related Equities
| ANEB | Anebulo Pharmaceuticals | 9.47 | ||||
| GNTA | Genenta Science | 1.06 | ||||
| RZLT | Rezolute | 0.76 | ||||
| LRMR | Larimar Therapeutics | 0.53 | ||||
| PRTC | PureTech Health | 0.42 | ||||
| MLYS | Mineralys Therapeutics, | 0.29 | ||||
| JANX | Janux Therapeutics | 1.27 | ||||
| FENC | Fennec Pharmaceuticals | 2.86 | ||||
| MOLN | Molecular Partners | 8.70 | ||||
| VRCA | Verrica Pharmaceuticals | 10.91 | ||||
| ACRV | Acrivon Therapeutics, | 13.95 |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.